Home
Live Updates
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder : comparemela.com
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...
Related Keywords
United States ,
Eiryw Roberts ,
Neurocrine Biosciences ,
Neurocrine Biosciences Inc ,
Linkedin ,
Takeda Pharmaceutical Company Ltd ,
Facebook ,
Twitter ,
Nasdaq ,
Chief Medical Officer ,
Depression Rating ,
Takeda Pharmaceutical Company ,
comparemela.com © 2020. All Rights Reserved.